hit optimisation

Views & Analysis

The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion.

Oncology

Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.